Justine Vanhevel

Justine Vanhevel

Auto-generated profile, based on publicly available information

Justine Vanhevel

Laboratory for the Cytogenetic and Molecular Diagnosis of Hematological Malignancies Centre for Human Genetics, University Hospitals Leuven Belgium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
JVJustine Vanhevel
Justine Vanhevel
LVLieve Verlinden
Lieve Verlinden
SDstefanie doms
stefanie doms
HWhans wildiers
hans wildiers
MVMieke Verstuyf
Mieke Verstuyf
The active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), is primarily known as a key regulator of calcium and phosphate homeostasis. It exerts its biological functions by binding to the vitamin D receptor (VDR), a transcription factor that regulates gene expression in vitamin D-target tissues such as intestine, kidney and bone. Yet, the VDR is expressed in many additional normal and cancerous tissues, where it moderates the antiproliferative, prodifferentiating and immune-modulating effects of 1,25(OH)2D3. Interestingly, several epidemiological studies show that low levels of 25(OH)D, a biological marker for 1,25(OH)2D3 status, are associated with an increased risk of breast cancer (BC) development. Mendelian randomization studies, however, did not find any relationship between single-nucleotide polymorphisms in genes associated with lower serum 25(OH)D and BC risk. Nevertheless, multiple and in vivo preclinical studies illustrate that 1,25(OH)2D3 or its less calcaemic structural analogues influence diverse cellular processes in BC such as proliferation, differentiation, apoptosis, autophagy and the epithelial–mesenchymal transition. Recent insights also demonstrate that 1,25(OH)2D3 treatment impacts on cell metabolism and on the cancer stem cell population. The presence of VDR in the majority of BCs, together with the various anti-tumoural effects of 1,25(OH)2D3, has supported the evaluation of the effects of vitamin D3 supplementation on BC development. However, most randomized controlled clinical trials do not demonstrate a clear decrease in BC incidence with vitamin D3 supplementation. However, 1,25(OH)2D3 or its analogues seem biologically more active and may have more potential anticancer activity in BC upon combination with existing cancer therapies.

1 December 2019 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
LVLieve Verlinden
Lieve Verlinden
IJIris Janssens
Iris Janssens
SDstefanie doms
stefanie doms
JVJustine Vanhevel
Justine Vanhevel
GCGeert Carmeliet
Geert Carmeliet
MVMieke Verstuyf
Mieke Verstuyf

3 January 2019 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
SDstefanie doms
stefanie doms
LVLieve Verlinden
Lieve Verlinden
JVJustine Vanhevel
Justine Vanhevel
IJIris Janssens
Iris Janssens
RBRoger Bouillon
Roger Bouillon
MVMieke Verstuyf
Mieke Verstuyf

18 June 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
JVJustine Vanhevel
Justine Vanhevel
KRKatrina Rack
Katrina Rack
GAGeneviève Ameye
Geneviève Ameye
HMHayat Mokrani
Hayat Mokrani
JBJolien De Bie
Jolien De Bie
BDBarbara Dewaele
Barbara Dewaele
Myeloid/Lymphoid Neoplasms with eosinophilia and involvement of Tyrosine Kinase gene fusions (MLN‐TK) is a WHO disease category including a diverse group of malignancies characterised by recurrent genomic rearrangements of tyrosine kinase (TK) genes such as PDGFRA, PDGFRB, FGFR1, JAK2, ETV6 and FLT3. Identification of these TK rearrangements is important for the accurate diagnosis of MLN‐TK and allows targeted therapy with TK inhibitors. In this study, we validated the use of optical genome mapping (OGM) retrospectively by analysing 11 samples from 10 cases with suspected or known TK rearrangements, previously analysed by current standard of care (SOC) methodologies, i.e., chromosome banding analysis (CBA), FISH and/or PCR‐based techniques. In six abnormal cases, OGM was able to detect the rearrangements previously determined by SOC methods. Furthermore, OGM identified the fusion partner in the JAK2‐ and PDGFRB‐rearranged cases and elucidated the mechanism underlying the BCR::FGFR1 and ETV6::SYK rearrangement. In two cases with a normal karyotype, OGM detected two cryptic FIP1L1::PDGFRA and TNIP1::PDGFRB rearrangements. In the two remaining cases, no abnormalities were detected either by OGM or SOC methods. We demonstrate that OGM is a valid technique for the diagnostic workflow of MLN‐TK, able to detect TK rearrangements and to identify unknown TK fusion partners.